21 research outputs found
Renal cell carcinoma: molecular pathways and targeted therapy
Renal cell carcinoma (RCC) is not a single disease. A number of different types of cancer occur in the kidney and each is caused by different genes with different histology and clinical course. Studies of hereditary kidney cancer sydromes have led to identification of the main kidney cancer genes: VHL, MET, FH, SDH, FLCN, TSC1 and TSC2. Mutations in each of these genes lead to dysregulation of at least one metabolic pathway that is mediated by oxygen, iron, energy and nutrient sensing suggesting that renal cell cancer is a disease of dysregulated cellular metabolism. A more improved understanding of molecular pathways has led to development of targeted therapies. Targeted agents against VEGF, VEGFR and mTOR continue to
play a crucial role in the management of metastatic RCC. However, complete response is extremely rare, resistance in tumor cells develops frequently and adverse effects of therapy are not unusual finding. For that reason further genetic and epigenetic changes, metabolic aberrations as well as immune response are beeing investigated in numerous studies to find new targets for more personalized therapy
U kojih bolesnika primijeniti hormonsku terapiju + docetaksel
Docetaxel improved the outcome of patients with mCSPC and became standard of care after CHAARTED , STAMPEDE arm C and GET UG-AFU 15 clinical trials and after subsequent meta-analysis. Patients with high-volume (CHAARTED definition) and high-risk (LATITUDE definition) disease, who have good performance status and are fit for chemotherapy, seem to benefit the most from addition of docetaxel to the androgen deprivation therapy. Results from TITAN trial with apalutamide showed the activity in the same setting. However, predictive biomarkers are still lacking. We have direct evidence of overall survival benefit from abiraterone, apalutamide and enzalutamide for patients with high-volume disease who are not fit for chemotherapy, as well as for patients with low-volume disease. Clinical trials will show is there place for triple therapy in clinical practice. Before obtaining the results of new clinical trial results, physicians should base their treatment decision on risks and benefits of each current approach and consider the patientĀ“s other health issues such as access, costs, patient and patientĀ“s preferences.UvoÄenje kemoterapije docetakselom je dovelo do unaprijeÄenja ishoda lijeÄenja u bolesnika s metastatskim senzitivnim rakom prostate te je dodatak docetaksela postao standard lijeÄenja Å”to je temeljeno na rezultatima studija CHAARTED, STAMPEDE, grane C i GET UG-AFU 15 studiji te nakon toga uÄinjene meta analize. Bolesnici s visokim volumenom bolesti (definicija po CHAARTED studiji) i visokog rizika (definicija prema LATIT UTDE studiji), koji imaju dobar performance
status i koji su pogodni za kemoterapiju, imaju najviÅ”e koristi od dodatka docetaksela androgenoj deprivacijskoj terapiji. Rezultati TITAN studije su pokazali aktivnosti apalutamida u istoj indikaciji. Ipak, prediktivni biomarkeri joÅ” uvijek nedostaju. Postoje jasni dokazi o koristi u ukupnom preživljenju od abiraterona, apalutamida i enzalutamida u bolesnika s bolesti visokog volumena koji nisu pogodni za kemoterapiju, kao i za bolesnike s bolesti niskog volumena. KliniÄke studije Äe
pokazati mjesto za trostruku terapiju u kliniÄkoj praksi. Prije objave rezultata novih kliniÄkih studija, lijeÄnici trebaju temeljiti svoje odluke na temelju procjene rizika i koristi svakog trenutnog pristupa i razmotriti druge parametre poput troÅ”kova lijeÄenja, dostupnosti skrbi te preferencije bolesnika
Rezultati lijeÄenja bolesnika s metastatskim rakom bubrega nivolumabom ā donacijskim programom na ime bolesnika (npp) u KliniÄkom bolniÄkom centru Zagreb
Field of metastatic renal cell cancer (mRCC) treatments is now evolving at a rapid and unprecedented pace. Nivolumab prolongs survival in patients with metastatic kidney cancer with a favorable safety profile as demonstrated in the Check-Mate 025 clinical trial. Nivolumab compared to everolimus prolonged survival in patients with mRCC while exibiting favorbale safety profile. In this study we present the results of nivolumab treatment in patients with mRCC within named patient program (NPP) at UHC Zagreb. In 30% of included patients survival was longer than 30 months and 16.6% patients had a complete response.PodruÄje lijeÄenja metastatskog raka bubrega (mRCC) je podruÄje ubrzanog razvoja terapijskih moguÄnosti. Nivolumab produljuje preživljenje bolesnika s metastatskim rakom bubrega uz dobar sigurnosni profil Å”to je pokazano u kliniÄkoj studiji CheckMate025. Nivolumab u usporedbi s everolimusom produljuje preživljenje kod bolesnika sa mRCC uz povoljni sigurnosni profil lijeka. U ovoj analizi smo prikazali rezultate lijeÄenja bolesnika nivolumabom u NPP u KliniÄkom bolniÄkom centru Zagreb tijekom 2016. do 2018. 30% bolesnika ima preživljenje dulje od 30 mjeseci, a 16.6% je imalo kompletni odgovor na terapiju
LijeÄenje germinativnog raka testisa
Germ-cell testicular cancer (GCTC) is a malignant neoplasm derived from the primordial germ cell. Although it accounts for approximately 1% of all malignancies in men, it is the most common cancer of younger male population, with the highest incidence between ages 15 and 35.
Testicular cancer incidence rate has risen globally over the past several decades, with the average increase in the incidence of testicular cancer in Croatia of 7% per annum from the year 1983 to 2007. Two main groups are seminomas and non-seminomas, each accounting for 50% of cases, and they differ in treatment modalities and response to therapy. Despite increase in the incidence rate, a promising circumstance is that GCTC has become a model of curable cancer. Because of advances in diagnostic procedures, sophisticated radiation techniques and especially the introduction of cisplatin based chemotherapy protocols together with advanced postchemotherapy surgical techniques, curability is expected in about 95% of all patients diagnosed with testicular cancer and over 70% of patients with advanced disease. In this review, we will focus on treatment strategies of primary GCTC.Germinativni rak testisa je maligna novotvorina podrijetla primordijalne zametne stanice. Iako Äini oko 1% svih malignih novotvorina muÅ”karaca, najÄeÅ”Äi je malignom mlaÄe muÅ”ke populacije s najveÄom incidencijom u dobi od 15 do 35 godina. Incidencija raka testisa poveÄala se globalno posljednjih nekoliko desetljeÄa, s prosjeÄnim porastom u incidenciji od 7% godiÅ”nje u Hrvatskoj u razdoblju od 1983. do 2007. godine. S obzirom na histoloÅ”ku sliku, germinativni rak testisa dijeli se na seminome i neseminome koji se razlikuju u naÄinu lijeÄenja i odgovoru na terapiju. UnatoÄ porastu u incidenciji, obeÄavajuÄa okolnost je da je rak testisa postao model izljeÄivog tumora. Zbog napretka u dijagnostiÄkim postupcima, sofisticiranih tehnika zraÄenja, a osobito uvoÄenja kemoterapijskih protokola baziranih na platini zajedno s naprednim postkemoterapijskim kirurÅ”kim tehnikama, izljeÄivost se oÄekuje u oko 95% svih dijagnosticiranih bolesnika s rakom testisa i oko 70% bolesnika s uznapredovalom boleÅ”Äu. U ovom preglednom radu usredotoÄit Äemo se na strategije lijeÄenja germinativnog raka testisa
Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report
Analiza bolesnika s metastatskim rakom bubrega srednje i loÅ”e prognostiÄke skupine lijeÄnih u KliniÄkom bolniÄkom centru Zagreb
Forty two to 57% of patients with metastatic renal cell carcinoma (mRCC) receive the second-line therapy according to available data. In our analysis we wanted to determine the percentage of patients within intermediate/poor prognostic group mRCC who continued the treatment with the second line following progression on the first line and the percentage of patients who were not able to receive the second line treatment. Patients received sunitinib (first started on 12 August 2018) or pazopanib (first started on May 2014) at University Hospital Center Zagreb. The latest treatment started in December 2018. Our results show that 39.4% of patients who received sunitinib and 37.9% of patients who received pazopanib, did not receive the second line treatment, which is consistent with available data. The question arises whether we could have helped those patients if we had access to newer therapeutic options.Prema literaturnim podacima oko 42% do 57% bolesnika smetastatskim karcinomom bubrega primi drugu liniju lijeÄenja. Retrospektivnom analizom naÅ”ih podataka htjeli smo prikazati postotak bolesnika s metastatskim karcinomom bubrega koji pripadaju srednjoj/loÅ”oj prognostiÄkoj skupini a koji su nastavili lijeÄenje drugom linijom nakon progresije na prvolinijsko lijeÄenje. TakoÄer smo htjeli prikazati postotak bolesnika koji nisu bili u moguÄnosti nastaviti drugolinijsko lijeÄenje. Bolesnici su primali sunitinib (prvi bolesnik je zapoÄeo lijeÄenje u svibnju 2014.) i pazopanib (prvi bolesnik je zapoÄeo lijeÄenje 12. kolovoza 2018) u KliniÄkom bolniÄkom centru Zagreb. UkljuÄeni su bili bolesnici koji su lijeÄenje zapoÄeli do kraja prosinca 2018. godine. 39.4% bolesnika koji su primali sunitinib i 37.9% bolesnika koji su primali pazopanib, nije primilo drugu liniju lijeÄenja, Å”to se podudara s literaturnim podacima. NameÄe se pitanje, jesmo li navedenim bolesnicima mogli pomoÄi da smo imali dostupne novije terapijske opcije
Taksani u lijeÄenju ranog raka dojke
Taxanes are irreplaceble drugs in treatment of many solid malignancies. In breast cancer they represent the backbone of adjuvant therapy and are important option in treatment of advanced and metastatic disease. Since their discovery in 1960ās they went through a long journey of clinical development and positioning in clinical practise of treatment of early breast cancer. Taxanes belong to the fourth group of cytotoxic drugs, which act as mytotic inhibitors, causing the death of the cell in metaphase. Clinical trials conducted in patients with breast cancer evaluated different combinations of other chemotherapeutics
with taxanes, different modes of administration, effectiveness of different chemotherapy regimens including taxanes in different subtypes and stages of the disease and effectiveness of individual taxanes in comparison with one another. Based on the results of those trials, today the relevant global oncology associations reccomend the use of taxanes in treatment of early breast cancer, pointing out their significant benefit in total reduction of breast cancer mortality and risk of disease reccurence by 20-30% comparing to anthracycline only protocols. The purpose of this literature review was to provide comprehensive information about development of taxanes and their position in routine everyday clinical practise.Taksani su nezamjenjivi lijekovi u lijeÄenju mnogih solidnih tumora. U karcinomu dojke predstavljaju okosnicu adjuvantne terapije i važna su opcija u lijeÄenju uznapredovale i metastatske bolesti. Od njihovog otkriÄa 1960-ih proÅ”li su dugi put kliniÄkog razvoja i pozicioniranja u kliniÄkoj praksi lijeÄenja ranog raka dojke. Taksani pripadaju Äetvrtoj skupini citotoksiÄnih lijekova koji djeluju kao inhibitori mitoze, koji uzrokuju smrt stanice u metafazi. KliniÄka istraživanja provedena
na bolesnicama s karcinomom dojke procjenjivala su razliÄite kombinacije drugih kemoterapeutika s taksanima, razliÄite naÄine primjene, djelotvornost razliÄitih kemoterapijskih protokola koji ukljuÄuju taksane u razliÄitim podtipovima i stadijima bolesti te uÄinkovitosti pojedinih taksana u usporedbi s drugim. Na temelju rezultata tih pokusa, danas relevantne globalne onkoloÅ”ke udruge preporuÄuju uporabu taksana u lijeÄenju ranog raka dojke, pokazujuÄi njihovu znaÄajnu korist u ukupnom smanjenju rizika od smrti i povrata bolesti za 20-30% u odnosu na protokole bazirane samo na antraciklinu. Svrha ovog pregleda literature je pružanje sveobuhvatne informacije o razvoju taksana i njihove pozicije u rutinskoj svakodnevnoj kliniÄkoj praksi
Primjena inhibitora kinaza u lijeÄenju bolesnika s uznapredovalim rakom Å”titnjaÄe
Although most patients with thyroid cancer have a favorable clinical course, some
patients develop a more aggressive type of cancer and exhibit more rapid disease progression with
worse prognosis. Those patients usually exhibit mutations of proteins such as tyrosine kinase enzymes
that play a significant role in regulation of tumor proliferation and spreading. Development of targeted
therapies is based on the inhibition of mutated kinases which are involved in the MAPK signaling
pathway. The aim of this study was to present the initial results of clinical experience with kinase
inhibitors in patients with metastatic differentiated thyroid cancer (DT C), poorly differentiated thyroid
cancer (PDT C), and medullary thyroid cancer (MTC) who exhibited rapid disease progression.
A total of 17 adult patients (11 women, mean age 53.3 years) managed for progressive, metastatic
disease were included in the study. Twelve patients with DT C and PDT C were previously tested for
BRAF mutations, of whom nine that had tumor tissue negative for the BRAF V600E mutation received
sorafenib, while three patients with tumors harboring the BRAF V600E mutation were treated
with vemurafenib. Patients with MTC were treated with sunitinib, vandetanib, and sorafenib. Two
patients with tumors harboring the BRAF mutation treated with vemurafenib showed restoration of
radioiodine uptake. Most of patients showed significant improvement in disease status but of limited
duration until disease progression. Although there was an improvement in progression-free survival,
future research has to achieve a greater and longer-lasting response, probably by utilizing combined
targeted therapy.Iako veÄina bolesnika s karcinomom Å”titnjaÄe ima povoljan kliniÄki tijek, ipak neki bolesnici pokazuju agresivniji tijek
bolesti s razvojem uznapredovalih formi tumora i loŔijom prognozom. Razlog su vjerojatno mutacije proteina, uglavnom
enzima tirozin kinaza koji imaju znaÄajnu ulogu u proliferaciji i rastu tumora. Razvoj ciljanih terapija zasnovan je na inhibiranju
mutiranih kinaza BRAF, MEK, NRAS, c-KIT koje su ukljuÄene u signalni put MAPK. U radu su predstavljeni preliminarni
rezultati lijeÄenja inhibitorima kinaza u bolesnika s metastatskim diferenciranim karcinomom Å”titnjaÄe (DT C),
slabo diferenciranim karcinomom Å”titnjaÄe (PDT C) i medularnim karcinomom Å”titnjaÄe (MTC). U izvjeÅ”Äe je ukljuÄeno
ukupno 17 odraslih bolesnika (11 žena, prosjeÄna dob 53,3 godine) lijeÄenih zbog progresivne, metastatske bolesti. Dvanaest
bolesnika s DT C i PDT C prethodno je testirano na BRAF mutacije. Devet bolesnika kod kojih je tumorsko tkivo bilo negativno
na mutaciju BRAF V600E primali su sorafenib, dok su tri bolesnika s tumorima koji nose mutaciju BRAF V600E
lijeÄena vemurafenibom u cilju rediferencijacije tumora, a u dva bolesnika doÅ”lo je do ponovne akumulacije radiojoda na
scintigramu tijela. Bolesnici s MTC-om lijeÄeni su sunitinibom, vandetanibom i sorafenibom. U veÄine bolesnika doÅ”lo je do
pozitivnog terapijskog odgovora uz poboljÅ”anje stanja, ali ograniÄenog trajanja. BuduÄa istraživanja bi trebala osigurati bolji
i trajniji terapijski odgovor, vjerojatno primjenom kombinirane ciljane terapije
RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS
Optimalno zbrinjavanje oboljelih od malignih bolesti, ovisno o vrsti tumora, ukljuÄuje i odreÄivanje serumskih tumorskih biljega. Ti su biljezi heterogena skupina molekula Äija je koncentracija poviÅ”ena kod ljudi oboljelih od zloÄudnih tumora, ali se u niskim koncentracijama mogu naÄi i u plazmi zdravih pojedinaca. PoviÅ”ene koncentracije u plazmi nastaju zbog: promjena u samoj stanici, nekroze stanice te promjene izražaja ili izluÄivanja razliÄitih molekula. Kod nekih tumora same tumorske stanice mogu potaknuti druge stanice na luÄenje odreÄenih spojeva. U kliniÄkoj primjeni u ovom je trenutku izmeÄu ostalih dostupno odreÄivanje nekoliko serumskih tumorskih biljega: CEA, CA 19-9, CA 15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH i tiroglobulin. VeÄi broj serumskih tumorskih biljega primjenjuje se eksperimentalno i Äeka svoje mjesto u svakodnevnoj kliniÄkoj primjeni. Smjernice o primjeni tumorskih biljega Nacionalne akademije kliniÄke biokemije (National Academy of Clinical Biochemistry ā NACB) osmiÅ”ljene su da bi poticale prikladniju upotrebu testova tumorskih biljega od lijeÄnika primarne zaÅ”tite, kirurga, onkologa, ginekologa te ostalih specijalista koji se bave bolesniĀcima sa solidnim tumorima.Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners,
surgeons, oncologists, and other health care professionals giving care to patients with solid tumours
Racionalna primjena serumskih tumorskih biljega u dijagnostici i lijeÄenju solidnih tumora [Rational use of serum tumour markers in diagnostics and treatment of solidtumours]
Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners, surgeons, oncologists, and other health care professionals giving care to patients with solid tumours